Skip to main content
. 2022 Feb 25;3(3):100560. doi: 10.1016/j.xcrm.2022.100560

Figure 5.

Figure 5

Comparative performance of the SCOPE score and suPAR to predict progression into severe respiratory failure (SRF) or death within the first 14 days in validation cohort I

(A) ROC curves of the SCOPE score and suPAR to predict progression into SRF or death within the first 14 days.

(B) Prognostic performance of SCOPE score values of 6 or more to predict progression into SRF or death within the first 14 days. The odds for patients with a score of 6 or more to progress into SRF or death are provided (calculation by Mantel Haenszel statistics).

(C) Prognostic performance of suPAR values of 6 ng/mL or more to predict progression into SRF or death within the first 14 days. The odds for patients with suPAR of 6 ng/mL or more to progress into SRF or death are provided (calculation by Mantel Haenszel statistics).

(D) The p values of comparisons of the AUC of ROC, of sensitivity, of specificity, of PPV, and of NPV of SCOPE score and of suPAR to predict progression into SRF or death within the first 14 days. AUC, area under the curve; CI, confidence interval; NPV, negative predictive value; n, number of patients; OR, odds ratio; PPV, positive predictive value; suPAR, soluble urokinase plasminogen activator receptor.